Posted by [ad_1]
hapabapa/iStock Editorial via Getty Images
Bristol Myers Squibb (NYSE:BMY) announced Saturday that its checkpoint inhibitors Opdivo and Yervoy, when combined, reduced the risk of disease progression or death by 38% in a Phase 3 trial for patients with a specific type of colorectal cancer.
Citing
[ad_2]